CIS BIOPHARMA is the Basel-based 2023 oncology spinoff from CIS Pharma. Christoph Schäfer,CEO of CIS Pharma, talks about his collaboration with 3Biotech.
Could you tell us about CIS?
We are a privately-held preclinical-stage biopharmaceutical company. Our assets comprise ADCs and radioligands, targeting cancer with high unmet need. Our capabilities and technologies allow for a unique approach as we create targeted therapies with payloads selected specifically per each molecular target and each indication. Our linker technology is expected to change the way ADCs and radioligands are used in the future.
In what context and at what stages did 3Biotech intervene in your project?
We have met 3Biotech in the context of planning of our CMC. I called on Olivier Favre Bulle for his reported expertise and the track record of his company 3Biotech.
How is 3Biotech's approach innovative and how has it contributed to your success?
The experience and knowledge of 3Biotech has been instrumental in planning CMC including the selection of vendors. By discussing critical success factors with Olivier - from a commercial as well as a regulatory perspective - we have quickly identified the criteria for evaluation of vendors.
What was the outcome? Success of this collaboration? Could you give me 3 key figures and 3 key facts about the project?
Based on the information provided by 3Biotech we have been able to identify the vendors most fit for our program and created a roadmap supporting discussions with investors.